SomatoKine User Fee Goal Date Extended to Oct. 3, Insmed Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The insulin-like growth factor therapy is under priority review for the orphan indication of growth hormone insensitivity syndrome. The original review deadline of July 3 is being extended to allow FDA time to review a major amendment to the NDA.